Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031691 · ClinicalTrials.gov registry record · Phase 1
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
A Phase 1 study of Metastatic Colorectal Cancer, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT03031691 is a Phase 1 study of Metastatic Colorectal Cancer that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 7 participants, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03031691, a Phase 1 study of Metastatic Colorectal Cancer, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination with Chemotherapy for Subjects with Previously Treated Metastatic Colorectal Cancer.
Conditions Studied
Interventions
- DRUG brontictuzumab
- DRUG trifluridine/tipiracil
Study Locations (5)
Florida
- Miami - Miami
- Sarasota - Sarasota
Colorado
- Denver - Denver
South Carolina
- Charleston - Charleston
Tennessee
- Nashville - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03031691
The ClinicalTrials.gov registry entry for NCT03031691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which brontictuzumab is the first listed.
NCT03031691 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Colorado, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03031691 about?
NCT03031691 is a clinical study titled "A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer". A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination with Chemotherapy for Subjects with Previously Treated Metastatic Colorectal Cancer.
What is the current status of trial NCT03031691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2017-01. Estimated completion is 2017-09.
What conditions does trial NCT03031691 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT03031691?
The interventions under investigation include: brontictuzumab (DRUG), trifluridine/tipiracil (DRUG).
Who is sponsoring clinical trial NCT03031691?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03031691 being conducted?
This trial has 5 study locations across Colorado, Florida, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 1
-
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.